Biotech Values

[jq1234]

Not necessarily. INCY CEO initially blamed patients for being too sick to be able to tolerate Jakafi. But he stopped doing that later on. It is not un-fixable situation, educate doctors for proper dose titration in INCY's case, or do dose reduction promptly for example.

Ultimately it can only put to rest from controlled trial results, but appropriate post marketing data can give more accurate picture of drug safety/tolerability in real world setting.